NASDAQ:CDXC
ChromaDex Corporation Stock News
$3.52
-0.310 (-8.09%)
At Close: May 09, 2024
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
08:34am, Wednesday, 24'th Apr 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will ho
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
08:32am, Wednesday, 21'st Feb 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference c
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
04:08pm, Friday, 26'th Jan 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IR--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief E
ChromaDex: Growth At A Reasonable Price
07:28pm, Tuesday, 23'rd Jan 2024
Nutraceuticals and supplements industry is gaining traction due to increasing demand for products that promote well-being. ChromaDex Corporation offers an interesting technology and product, Niagen, w
ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript
09:02pm, Wednesday, 08'th Nov 2023
ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
08:34am, Tuesday, 31'st Oct 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference c
ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript
08:32pm, Wednesday, 09'th Aug 2023
ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Bria
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
08:02am, Wednesday, 02'nd Aug 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, Au
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
08:34am, Thursday, 11'th May 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, a
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
ChromaDex (CDXC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.11 per share a year ago.
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
08:32am, Tuesday, 02'nd May 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference c
ChromaDex Corporation (CDXC) Q4 2022 Earnings Call Transcript
09:42pm, Wednesday, 08'th Mar 2023
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive O
ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates
07:33pm, Wednesday, 08'th Mar 2023
ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
08:32am, Monday, 27'th Feb 2023
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference ca
Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround
11:17am, Monday, 19'th Dec 2022
The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts